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ABSTRACT
All HIV-1-infected individuals develop strain-specific neutralizing antibodies to their infecting virus, which in some cases ma-
ture into broadly neutralizing antibodies. Defining the epitopes of strain-specific antibodies that overlap conserved sites of vul-
nerability might provide mechanistic insights into how broadly neutralizing antibodies arise. We previously described an HIV-1
clade C-infected donor, CAP257, who developed broadly neutralizing plasma antibodies targeting an N276 glycan-dependent
epitope in the CD4 binding site. The initial CD4 binding site response potently neutralized the heterologous tier 2 clade B viral
strain RHPA, which was used to design resurfaced gp120 antigens for single-B-cell sorting. Here we report the isolation and
structural characterization of CAP257-RH1, an N276 glycan-dependent CD4 binding site antibody representative of the early
CD4 binding site plasma response in donor CAP257. The cocrystal structure of CAP257-RH1 bound to RHPA gp120 revealed
critical interactions with the N276 glycan, loop D, and V5, but not with aspartic acid 368, similarly to HJ16 and 179NC75. The
CAP257-RH1 monoclonal antibody was derived from the immunoglobulin-variable IGHV3-33 and IGLV3-10 genes and neutral-
ized RHPA but not the transmitted/founder virus from donor CAP257. Its narrow neutralization breadth was attributed to a bind-
ing angle that was incompatible with glycosylated V5 loops present in almost all HIV-1 strains, including the CAP257 transmitted/
founder virus. Deep sequencing of autologous CAP257 viruses, however, revealed minority variants early in infection that lacked V5
glycans. These glycan-free V5 loops are unusual holes in the glycan shield that may have been necessary for initiating this N276 glycan-
dependent CD4 binding site B-cell lineage.
IMPORTANCE
The conserved CD4 binding site on gp120 is a major target for HIV-1 vaccine design, but key events in the elicitation and matu-
ration of different antibody lineages to this site remain elusive. Studies have shown that strain-specific antibodies can evolve into
broadly neutralizing antibodies or in some cases act as helper lineages. Therefore, characterizing the epitopes of strain-specific
antibodies may help to inform the design of HIV-1 immunogens to elicit broadly neutralizing antibodies. In this study, we iso-
late a narrowly neutralizing N276 glycan-dependent antibody and use X-ray crystallography and viral deep sequencing to de-
scribe how gp120 lacking glycans in V5 might have elicited these early glycan-dependent CD4 binding site antibodies. These data
highlight how glycan holes can play a role in the elicitation of B-cell lineages targeting the CD4 binding site.
Neutralizing antibodies to the HIV-1 envelope (Env) glycopro-tein generally appear in all individuals within months of in-
fection (1–4). These antibodies target highly sequence-variable
epitopes that are fully accessible on prefusion Env trimers, such as
the immunodominant, solvent-exposed, hypervariable regions
V1 to V5 (2, 3, 5–8). As a result, these early neutralizing antibodies
are strain specific for the transmitted/founder virus and rapidly
select for escape mutants that drive Env diversification (6).
Broadly neutralizing antibodies (bNAbs) that are able to cross-
neutralize diverse HIV-1 strains by targeting structurally or func-
tionally conserved regions of Env develop in some individuals
later in infection (9–14). Animal studies have shown that bNAbs
have the capacity to prevent infection and are likely the types of
antibodies that will need to be elicited by an HIV-1 vaccine (15,
16). Significant effort has therefore gone into designing bNAb-
initiating immunogens and understanding how bNAb precursors
become broadly neutralizing. Studies defining the ontogeny of
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bNAbs have shown that they can develop from strain-specific pre-
cursors through affinity maturation, suggesting that in addition to
recognizing hypervariable loop regions, strain-specific neutraliz-
ing antibodies might also overlap the conserved epitopes recog-
nized by bNAbs (17–20). Furthermore, strain-specific or narrowly
neutralizing antibodies have the potential to cooperate with other
lineages in driving overall viral diversity, which in turn creates
stimuli for the diversification of bNAbs (21, 22). Thus, studies of
strain-specific antibodies are providing important insights for
understanding how antibody lineages acquire neutralization
breadth.
A large number of bNAbs targeting the CD4 binding site
(CD4bs) have been isolated from HIV-1-infected individuals (18,
23–28). These antibodies can be adsorbed out of complex poly-
clonal sera by gp120 monomers, making them ideal candidates for
isolation by flow cytometry. High-resolution crystal structures in
complex with Env antigens have made this the most well-charac-
terized site of vulnerability on the HIV-1 envelope (25, 26, 29).
Two classes of CD4bs bNAbs have been described: the variable
heavy (VH) gene-restricted class and the heavy chain complemen-
tarity-determining region 3 (CDR-H3)-dominated class. VH
gene-restricted bNAbs all develop from the germ line-encoded
immunoglobulin heavy chain variable gene IGHV1-2 or
IGHV1-46 and were defined by prototypical antibodies VRC01
and 8ANC131 (25, 26, 29, 30). This class has a germ line-encoded
arginine residue at position 71 in CDR-H2 that mimics an argi-
nine at position 59 in CD4 by interacting with aspartic acid 368 in
the CD4 binding loop of gp120. Over half of the VRC01 interac-
tion with gp120 is mediated by CDR-H2 (30). As a result, VH
gene-restricted CD4bs bNAbs are all similarly oriented with re-
spect to Env. This angle of approach positions the light chains of
IGVH1-2/46-derived CD4bs antibodies proximal to loop D in
gp120, causing steric clashes with loop D and/or the glycan at
position N276, which is thought to severely hamper the initiation
of VH gene-restricted CD4bs bNAb lineages (31, 32). In contrast,
members of the CDR-H3-dominated class of CD4bs antibodies
are derived from a wider variety of IGHV genes and bind to Env
with diverse angles of approach that are not impeded by the N276
glycan (26). Antibodies VRC13 (IGVH1-69), VRC16 (IGVH3-
23), and CH103 (IGVH4-59) all form important interactions with
D368 that develop through affinity maturation or germ line V-D-J
recombination, similarly to VH1-2/46 class antibodies. A sub-
group of the CDR-H3-dominated class, which includes HJ16
(IGVH3-30) and the more recently described antibody 179NC75
(IGVH3-21), has a different mode of recognition, where neutral-
ization is independent of interactions with D368 but critically de-
pendent on the N276 glycan (the same glycan that obstructs VH1-
2/46 binding) (28, 33). Recombinant Env-derived proteins with a
glycan deletion at position N276 are able to engage the germ line-
reverted antibodies of many IGVH1-2/46-derived CD4bs bNAbs
and have been proposed as HIV-1 vaccine immunogens (34, 35).
Additional glycan deletions in V5 enable even better binding to
VH gene-restricted bNAb precursors (32). These glycan deletions
create large holes in the glycan shield, but their effects on Env
antigenicity, and the immunogenicity of the CD4bs, remain to be
determined.
We previously characterized the bNAb responses in plasma
from donor CAP257, a participant of the CAPRISA cohort (36).
Donor CAP257 developed three distinct waves of bNAbs that ap-
peared sequentially in plasma, first targeting the V2 epitope, then
targeting the CD4bs, and finally targeting a third, as-yet-unde-
fined epitope. Donor CAP257 CD4bs bNAbs appeared between 50
and 60 weeks postinfection, with titers peaking at 122 weeks
postinfection and declining thereafter. These bNAbs were criti-
cally dependent on the N276 glycan, and unlike most previously
described CD4bs bNAbs, they could be readily adsorbed with
D368R mutant gp120s. This CD4bs plasma bNAb response could
be further divided into early and late CD4bs antibodies based on
sensitivity to an N279D escape mutation that arose in the viral
quasispecies at 93 weeks postinfection. Early CD4bs antibodies
potently neutralized the tier 2 clade B strain RHPA but had very
narrow neutralization breadth and were abrogated by the D279
immunotype. Late CD4bs antibodies were tolerant of the D279
immunotype, and this coincided with the acquisition of greater
neutralization breadth. These broader antibodies were escaped
first by mutations that removed the N276 glycan at 122 weeks
postinfection and then by bulky aromatic side chain substitutions
at position R456 in the base of V5 by 163 weeks postinfection.
Here, we designed RHPA-derived sorting antigens to isolate an
early member of the CD4bs neutralizing antibody response, called
CAP257-RH1, from donor CAP257 memory B cells. A cocrystal
structure of CAP257-RH1 in complex with RHPA gp120 that in-
cluded the N276 glycan revealed a CDR-H3-dominated interface
that significantly overlapped the epitopes of CD4bs bNAbs.
CAP257-RH1 neutralized one virus, RHPA, out of a large multi-
clade panel, and this heterologous strain specificity was explained
by a binding angle that was incompatible with the V5 glycans
present in most HIV-1 strains. Analysis of donor CAP257 autolo-
gous viruses by deep sequencing revealed a minority population
with glycan-free V5 loops similar to those of RHPA, which may
have initiated this lineage or provided the antigenic stimuli that
allowed it to mature. These findings provide a mechanism for the
strain specificity of early CD4bs neutralizing antibodies in donor
CAP257, which target a rare glycan hole in V5 and have implica-
tions for the use of HIV-1 immunogens that are aimed at activat-
ing CD4bs bNAb precursors by removing key loop D and/or V5
loop glycans.
MATERIALS AND METHODS
Ethics statement. The CAPRISA 002 Acute Infection cohort is comprised
of women at high risk of HIV-1 infection in KwaZulu-Natal, South Africa.
The CAPRISA Acute Infection study received ethical approval from the
Universities of KwaZulu-Natal (E013/04), Cape Town (025/2004), and
the Witwatersrand (MM040202). Donor CAP257 provided written in-
formed consent for study participation. Blood samples were collected at
regular intervals from seroconversion through to the initiation of antiret-
roviral therapy, processed, and cryopreserved individually.
Cell culture and pseudovirus preparation. 293F suspension cells
were cultured in 293Freestyle medium (Gibco BRL Life Technologies) at
37°C in 10% CO2 at 125 rpm. HEK293S (GntI
/) cells were cultured in
suspension as described above but supplemented with 2% heat-inacti-
vated fetal bovine serum (FBS). Adherent CD4 CCR5 TZM-bl HeLa
and HEK293T cells were grown to confluence in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS, 22.7 mM HEPES
(Gibco BRL Life Technologies), and 50 g/ml gentamicin (Sigma) at 37°C
in 5% CO2. Monolayers were disrupted with 0.25% trypsin in 1 mM
EDTA (Sigma). For pseudoviruses, HEK293T cells were seeded in 10 ml at
2  106 cells/ml in 10-cm2 dishes. Twenty-four hours later, plasmids
expressing the Env protein of interest and the pSG3Env backbone (ob-
tained from the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH) were cotransfected by using a 3:1 ratio of
PEI-Max 40,000 (Polysciences). Cultures were incubated for 48 h at 37°C,
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filtered through a 0.45-m filter, and frozen in 20% FBS. Mutant Env
plasmids were made with the QuikChange Lightning kit (Stratagene).
ELISA. High-binding enzyme-linked immunosorbent assay (ELISA)
plates were coated with recombinant gp120 at 4 g/ml in Carb/Bicarb
buffer at 4°C at pH 10 overnight. Plates were washed between each sub-
sequent step four times with phosphate-buffered saline (PBS) containing
0.05% Tween 20. Blocking was done with 5% skim milk powder in PBS for
1 h at 37°C. Serial dilutions of HIV-1 monoclonal antibodies (MAbs) in
5% skim milk powder in PBS were added for 1 h at 37°C, and complexes
were detected with an anti-Fc-horseradish peroxidase (HRP) conjugate.
ELISA reactions were propagated in 100 l of the enzyme substrate for 5
min and stopped with 25 l of 1 M H2SO4. The absorbance was read at
450 nm.
Neutralization assays. Neutralization assays, performed as previously
described (3, 37), were used to measure the reduction in relative light
units after a single round of pseudovirus infection in the presence of a
monoclonal antibody or plasma sample. Samples were serially diluted 1:3,
and the 50% inhibitory dose (ID50)/50% inhibitory concentration (IC50)
was calculated as the dilution at which infection was reduced by 50%.
Adsorption assays. Protein aliquots of 400 g each were coupled to
MyOne tosyl-activated magnetic Dynabeads (Invitrogen) at 37°C at pH
9.5 overnight and then blocked with 0.5% bovine serum albumin (BSA) in
0.0 5% Tween 20 –PBS overnight at 37°C. Protein-conjugated beads were
incubated with 200 l of plasma (diluted 1:20) for 2 h at 37°C, the beads
were then removed magnetically, and the remaining plasma was assessed
for binding and neutralizing antibodies by using ELISAs and neutraliza-
tion assays, respectively.
B-cell sorting. The positive RHPA-RC and negative RHPA-ADW
gp120 antigens were engineered with a C-terminal AviTag, and the pro-
teins were biotinylated postexpression by using a bulk BirA biotinylation
kit (Avidity). Biotinylated sorting antigens were conjugated to streptavi-
din labeled with Alexa Fluor 647 (AF647) or brilliant violet 420 (BV420)
and titrated for flow cytometry. Thawed peripheral blood mononuclear
cells (PBMCs) were stained with sorting probes as well as the Live/Dead
Aqua viability marker (Invitrogen, Carlsbad, CA), CD3-phycoerythrin
(PE), CD14-PE, CD16-PE, IgD-fluorescein isothiocyanate (FITC), and
CD19-allophycocyanin (APC)-Cy7 (BD Biosciences). Single sorted cells
were frozen in RNase-free buffer. Flow cytometric data were acquired on
a BD Aria 2 fluorescence-activated cell sorter (FACS), and the data were
analyzed by using FlowJo (TreeStar).
Immunoglobulin gene amplification. Single B-cell heavy and light
chain mRNA transcripts were reverse transcribed by using random hex-
amers and amplified by nested PCR in five different primer pools (three
distinct sets for groups of variable heavy chain genes) as previously de-
scribed (38, 39). Second-round PCRs introduced restriction sites that
were used to clone the antibodies into mammalian expression vectors for
IgG expression.
X-ray protein crystallography. The CAP257-RH1 monoclonal anti-
body containing a human rhinovirus (HRV) 3C protease cleavage site
after the antigen binding fragment (Fab) was bound to protein A and used
to purify an RHPA gp120 core that had already been enriched by Ni-
nitrilotriacetic acid (NTA) chromatography (30 mM imidazole wash and
400 mM imidazole elution buffers at pH 7). The Fab-gp120 complexes
were eluted with HRV3C and further purified by gel filtration using a
Superdex 200 column (GE Healthcare). Complexes were concentrated to
8 mg/ml, aliquoted, and flash frozen in the presence of endoglycosidase
H (Endo H) at 200 U/ml. Aliquots were thawed immediately before
crystallization drops were set up. Two-hundred-nanoliter crystallization
screens (containing 50% mother liquor) were set up under 576 conditions
in 96-well sitting-drop vapor diffusion plates (Corning) at 25°C, using
Cartesian Honeybee and TTP Labtech Mosquito crystallization robots. A
single crystal hit was hand-optimized in 15-well hanging-drop diffusion
plates using 1-l drops at 25°C. The final crystallization conditions con-
sisted of a solution containing 0.1 M HEPES (pH 7.5), 8% polyethylene
glycol 4000 (PEG 4000), and 10% isopropanol, and crystals were flash
frozen in 15% 2R,3R-butanediol or 25% 2,4-methylpentanediol as a cryo-
protectant. Once mounted onto the goniometer, only 5% of the crystals
yielded measurable X-ray diffraction, and this was considerably improved
after these crystals were annealed in situ by diverting the cryostream for 3
s. Two of the crystals diffracted to a final resolution of 3.2 Å. Diffraction
data were collected at the Advanced Photon Source (Argonne National
Laboratory) SER-CAT ID-22 beamline, at a wavelength of 1.00 Å at 100K,
and processed with HKL2000. The structure was solved by molecular
replacement using the PHENIX v1.9-1692 software package and search
models under PDB accession no. 4JZZ, 1NL0, and 4HPY. Models were
refined with hydrogens to minimize clashes in COOT v0.8 using 5% of the
data as an Rfree cross-validation test set. All structural images were gener-
ated with the PyMOL Molecular Graphics System, Version 1.3r1edu
(Schrodinger LLC).
Next-generation sequencing library preparation. RNA extraction,
cDNA synthesis, and subsequent amplification were carried out as de-
scribed previously (40), with the following modifications. A minimum of
5,000 HIV-1 RNA copies were isolated from longitudinal plasma samples
spanning 3.5 years of infection by using the QIAamp viral RNA kit
(Qiagen). The cDNA synthesis primer was designed to bind to the C5
region of the HIV-1 envelope gene (HXB2 gp160 DNA positions 1408 to
1431) and included a randomly assigned 9-mer tag (Primer ID method) to
uniquely label each cDNA molecule, followed by a universal primer bind-
ing site to allow out-nested PCR amplification of cDNA templates. First-
round amplification primers were designed to bind to the end of the V3
loop (HXB2 gp160 DNA positions 890 to 911) and contained a template-
specific binding region, followed by a variable-length spacer of 0 to 3
randomly assigned bases to increase sample complexity. In addition, PCR
primers contained 5= overhangs, introducing binding sites for the Nextera
XT indexing primers (Illumina). This allowed the amplification of the
C3-to-V5 region of the envelope spanning HXB2 gp160 positions 911 to
1408. Nested PCRs were carried out by using the Nextera XT indexing kit.
After indexing, samples were purified by using SPIRselect magnetic beads
(Beckman Coulter) with a sample volume-to-bead ratio of 1:0.65 for the
removal of 300-bp fragments. Sample concentrations were quantified
by using the Qubit dsDNA HS assay (Thermo Fisher) and pooled in
equimolar concentrations. The pooled amplicons were gel extracted by
using the QIAquick gel purification kit (Qiagen) to ensure primer re-
moval before the final library was submitted for sequencing on an Illu-
mina MiSeq instrument, using 2-by-300-bp paired-end chemistry.
Next-generation sequencing data processing and analysis. Raw
reads were processed by using a custom pipeline housed within the Uni-
versity of Cape Town High-Performance Computing core. Read quality
was assessed by using fastqc (http://www.bioinformatics.babraham.ac.uk
/projects/fastqc). Short reads (150 bp) were filtered out by using Trim-
momatic (41), and reads with an average quality score of less than 20 were
removed by using a custom python script. A low Q score cutoff was used,
as the Primer ID method removes sequencing and PCR errors during the
consensus sequence generation step. The overlapping forward and reverse
reads were merged by using PEAR (42), and the forward primer sequence
was stripped out of all reads by using a custom python script. Reads where
the forward primer could not be found were discarded. An in-house pro-
gram, developed in R, was used to bin all reads containing an identical
Primer ID tag, align the reads within each bin using MAFFT (43), and
produce a consensus sequence based on a majority rule. Consensus se-
quences from bins of a size n (where n is the maximum size of offspring
bins expected to result from sequencing error in the PID of the largest bin
and has a mean value of 15 for this data set) were filtered out by using a
cutoff model described previously (44). Consensus sequences containing
degenerate bases, frameshift mutations, or stop codons were also re-
moved. Custom python scripts were used to calculate and plot the num-
ber and frequency of glycosylation sites in the V5 loop.
Accession number(s). The structure reported here is available under
PDB accession no. 5T33.
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Design of a resurfaced gp120 core sorting antigen based on tier 2
strain RHPA. We have previously shown that the CD4bs neutral-
izing antibodies in plasma from donor CAP257 were similar to
HJ16 (36) and could not be adsorbed with the resurfaced stabi-
lized gp120 core (RSC3) sorting antigen used to isolate VRC01.
Therefore, a new sorting antigen was engineered for donor
CAP257 B-cell isolation based on tier 2 strain RHPA, which was
highly sensitive (ID50 titer of 1:8,000) to the CD4bs antibodies of
donor CAP257. Similarly to RSC3, the RHPA gp120 sorting anti-
gens were truncated in the V1-V3 loops as well as the N and C
termini and resurfaced with 47 rare mutations in surface-exposed
but normally conserved residues outside the CD4bs (Fig. 1A; see
also Fig. S1A in the supplemental material) (24). Hypervariable
regions are unlikely to be reactive with heterologous antibodies
and were not resurfaced. The RSC3 cavity-filling mutations
(M95W, T257S, S375W, and A433M) and cystine bonds near loop
D (W96C/V275C) that were previously designed to stabilize
gp120 in the CD4-bound conformation were avoided, because it
was not known how they might affect the CAP257 epitope, which
differed from VRC01-like antibodies (36). This resurfaced core
gp120, called RHPA-RC, bound to conformation-sensitive neu-
tralizing antibodies VRC01 and 2G12, confirming that resurfacing
mutations did not compromise protein folding (data not shown).
To enhance the specificity for CAP257 CD4bs antibodies, we also
created a negative sorting antigen, called RHPA-ADW, which in-
cluded three mutations in gp120 loop D and the base of V5
(T278A, N279D, and R456W) that we have previously shown to
contribute to escape from the CD4bs neutralizing antibodies in
donor CAP257 plasma (Fig. 1A, green) (36). The negative antigen
RHPA-ADW did not bind strongly to CD4bs antibody VRC01 as
expected but still bound well to 2G12, confirming the antigen’s
conformational integrity and its ability to select for CD4bs anti-
body responses (data not shown).
The ability of CAP257 CD4bs antibodies to bind to either the
positive RHPA-RC antigen or the negative RHPA-ADW antigen
was assessed by ELISAs and adsorption assays. Remarkably, the
longitudinal kinetics of CAP257 plasma antibody binding to the
positive antigen RHPA-RC tracked with the neutralization of
the RHPA parent strain, with titers increasing or decreasing at
similar time points throughout infection (Fig. 1B). Similarly,
CAP257 plasma antibodies did not bind well to the negative anti-
gen RHPA-ADW, although they showed weak binding at between
161 and 174 weeks postinfection that tracked with the neutraliza-
tion of the more resistant RHPA-ADW mutant virus (Fig. 1B).
Adsorption experiments using donor CAP257 plasma at 122
weeks postinfection, when the CD4bs antibody titers had peaked,
showed that the positive antigen RHPA-RC could efficiently ad-
sorb the CD4bs neutralizing antibodies against RHPA (a clade B
virus), Q23 and Q842 (clade A), and CAP61 (clade C), while the
negative antigen RHPA-ADW could not (Fig. 1C). Altogether,
these data suggested highly specific selection for CAP257 CD4bs
neutralizing antibodies by the combination of the positive
RHPA-RC and negative RHPA-ADW sorting probes.
FIG 1 Resurfaced RHPA gp120 antigens bind differentially to CAP257 CD4bs plasma antibodies. (A) Surface view of a modeled RHPA gp120 core showing the
location of N/C-terminal truncations; deleted V1, V2, or V3 loops; resurfacing mutations; and the N276D/T278A, N279D, and R456W escape mutations, relative
to the CD4 binding site. Hypervariable regions 	2, 
14, V4, and V5 were not resurfaced. (B) Comparison of the abilities of longitudinal donor CAP257 plasma
samples to bind to the newly designed gp120 core sorting antigens RHPA-RC and RHPA-ADW by ELISAs and neutralization of the heterologous tier 2 strain
RHPA or the RHPA-ADW mutant variant resistant to CAP257 CD4bs antibodies. The lack of binding to RSC3 is shown in gray. Absorbance readings are plotted
on the left y axis, neutralization titers are plotted on the right y axis, and time course postinfection is plotted on the x axis. The vertical dotted line indicates the
122-week time point at which the adsorption experiments described below for panel C were performed. (C) Adsorption of CAP257 peak CD4bs neutralizing titers
by the positive gp120 antigen RHPA-RC but not the negative gp120 antigen RHPA-ADW or uncoated beads. Neutralization of four HIV-1 strains by donor
CAP257 plasma that had been adsorbed with blank beads or beads coated with the positive gp120 antigen RHPA-RC or the negative gp120 antigen RHPA-ADW
is plotted on the y axis as percent inhibition. Serial dilutions of the adsorbed plasma are indicated on the x axis.
N276-Dependent CD4bs Antibody Targets a V5 Glycan Hole
November 2016 Volume 90 Number 22 jvi.asm.org 10223Journal of Virology
 on A







Isolation of an N276 glycan-dependent CD4bs B-cell lineage.
A PBMC sample obtained at 107 weeks postinfection, when the
CD4bs lineage was likely to be expanding, was selected for B-cell
isolation. Single memory B cells were sorted as CD3 CD14
CD16 IgD RHPA-ADW CD19 RHPA-RC by flow cytom-
etry (Fig. 2A). At least one antibody heavy or light chain could be
recovered from 65% of the 94 sorted cells, and DNA sequencing
revealed that RHPA-RC selected for three antibody lineages. The
first of these lineages was a family of five IGHV4-59/61 heavy
chains that were 16% to 18% mutated from the germ line and
shared the same heavy chain family as CD4bs antibody CH103
(see Fig. S2A in the supplemental material). However, the paired
light chains for this antibody family could not be recovered. Sim-
ilarly, a family of six unpaired IGKV1-NL1 light chains that were
between 5% and 16% mutated were also isolated but could not be
functionally assessed without complementary heavy chain se-
quences (see Fig. S2B in the supplemental material). The third
family was derived from IGHV3-33 heavy and IGLV3-10 light
chains and is referred to here as the CAP257-RH lineage (Fig. 2B;
see also Fig. S2C in the supplemental material). CAP257-RH
heavy and light chain genes were 8 to 11% and 4 to 13% mutated,
respectively, and had relatively normal CDR-H3 and CDR-L3
lengths of 11 amino acids each (Kabat numbering). One of these
antibodies, CAP257-RH1, bound well to the wild-type RHPA
gp120 core by ELISAs and bound weakly to the positive sorting
antigen RHPA-RC (similarly to bNAb HJ16) but did not bind to
the negative sorting antigen RHPA-ADW (Fig. 2C), confirming
the specific selection of CAP257-RH lineage antibodies.
CAP257-RH1 displays strain-specific heterologous neutral-
ization and gp120 binding. We have previously shown that es-
FIG 2 Isolation of an early N276 glycan-dependent CD4bs neutralizing antibody. (A) Sort plot showing the percentage of identified memory B cells that were
able to bind the positive sorting antigen RHPA-RC (fluorescence plotted on the y axis) but not to the negative sorting antigen RHPA-ADW (fluorescence plotted
on the x axis). (B) Properties of the CAP257-RH lineage members, defined by the International Immunogenetics database (IMGT) and numbered according to
Kabat numbering. (C) Comparison of the binding of CAP257-RH1 or HJ16 to wild-type RHPA core gp120 (no symbols) as well as to the positive gp120 sorting
antigen RHPA-RC or the negative gp120 sorting antigen RHPA-ADW by ELISAs. Absorbance is plotted on the y axis versus the antibody concentration on the
x axis. (D) Neutralization of RHPA and select mutants with various levels of resistance to CAP257 CD4bs plasma antibodies by either donor CAP257 plasma at
107 weeks postinfection or the CAP257-RH1 monoclonal antibody isolated at the same time point. Percent neutralization is plotted on the y axis, and the dilution
is plotted on the x axis. (E) ELISA binding of an anti-HIV immunoglobulin pool (positive control) or monoclonal antibody CAP257-RH1 to 11 clade C gp120
proteins. (F) Neutralization of seven heterologous viruses sensitive to early CAP257 CD4bs antibodies by either donor CAP257 plasma at 107 weeks postinfection
(p.i.) or monoclonal antibody CAP257-RH1. Increasing potency is indicated by warmer colors.
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cape from CAP257 CD4bs antibodies was due to the sequential
appearance of three mutations at positions 279, 276/278, and 456.
The N279D immunotype switch appeared first and preceded the
acquisition of breadth. Mutations that deleted the glycosylation
sequon at position N276 (e.g., T278A) appeared next, while the
R456W substitution was the last major escape mutation (36).
These CD4bs mutants were used to compare the neutralization of
MAb CAP257-RH1 to a contemporaneous plasma sample from
107 weeks postinfection (Fig. 2D). The plasma samples obtained
at 107 weeks postinfection neutralized RHPA at ID50 titers exceed-
ing 1:1,000 and by this time had already adapted to tolerate the
early D279 escape mutation but were still dependent on N276 and
R456 for effective neutralization (Fig. 2D, left). CAP257-RH1 po-
tently neutralized RHPA with an IC50 of 0.11 g/ml (Fig. 2D,
right). This neutralization was completely abrogated by N276Q
and T278A mutations that removed the N276 glycan, confirm-
ing that CAP257-RH1 was a component of the CAP257 CD4bs
plasma neutralizing response (Fig. 2D). However, unlike CAP257
plasma, CAP257-RH1 neutralization was substantially reduced
(100-fold) by the early N279D mutation and unaffected by the late
R456W change. These data suggest that CAP257-RH1 appeared
very early in the CAP257 CD4bs neutralizing response, before the
emergence of CD4bs-specific neutralization breadth.
The cross-reactivity and breadth of MAb CAP257-RH1 were
further examined by ELISAs and neutralization assays, respec-
tively (Fig. 2E and F). CAP257-RH1 showed binding to RHPA
gp120 but was unable to bind any of the 11 heterologous clade C
gp120 monomers tested, all of which were bound by a pooled
HIV-positive (HIV) immunoglobulin control (HIV-Ig) (Fig.
2E). Similarly, CAP257-RH1 displayed strain-specific heterolo-
gous neutralization of only RHPA among the 196-virus multi-
clade panel tested, including other viruses neutralized by early
CAP257 CD4bs neutralizing antibodies (Fig. 2F; see also Table S1
in the supplemental material). CAP257-RH1 did not display in-
complete neutralization maxima, as seen with a number of re-
cently isolated glycan-dependent HIV-1 bNAbs (45).
Structural classification of CAP257-RH1 as a CDR-H3-dom-
inated class CD4bs antibody. A cocrystal structure of the
CAP257-RH1 Fab region bound to RHPA core gp120 was deter-
mined to 3.2-Å resolution (Table 1 and Fig. 3A). The structure
included an (N-acetylglucosamine)2(mannose)5 (NAG2MAN5)
glycan at position N276 bound in the paratope (Fig. 3A, light
green) and confirmed the CD4bs as the target for CAP257-RH1
neutralization. The crystallization conditions included Endo H to
facilitate slow, in-drop deglycosylation of gp120, since preincuba-
tion with Endo H disrupted the Fab-gp120 complexes; however,
the enzyme was present at a very low concentration and did not
contribute to the asymmetric unit. The CAP257-RH1 angle of
approach was compatible with Env oligomerization and did not
clash with the V1V2 domain (Fig. 3B), as was seen previously for
other narrowly neutralizing CD4bs antibodies (46, 47). The inter-
face between CAP257-RH1 and RHPA gp120 buries a total surface
area of 1,184 Å2, to which the heavy chain contributes 593 Å2
and the light chain contributes 594 Å2 (Fig. 3C; see also Tables
S2 to S4 in the supplemental material). Unlike other CD4bs anti-
bodies, CAP257-RH1 does not extend its CDRs deep into the cav-
ity bound by CD4 but instead interacts with more peripheral re-
gions of the CD4bs, including loop D, V5, and the CD4 binding
loop (Fig. 3C and D; see also Fig. S3 in the supplemental material).
Accordingly, protein-protein interactions with gp120 account for
748 Å2 of the total buried surface area. More than one-third of
the total interface (436 Å2) involves interactions with the N276
glycan, which fits snugly at the heavy chain-light chain interface,
where each chain contributes 201 Å2 and 235 Å2 of bound
surface area, respectively. This area is similar to the 300 Å2 to 400
Å2 buried by N276 in the interfaces of some VRC01 relatives,
which are not glycan dependent, but is only half as large as the
interface with N276 made by 8ANC195 (48–50). The gp120 used
for these crystallization experiments was expressed in HEK293S
GntI/ cells to facilitate deglycosylation at pH 7. As a result, the
cocrystal structure includes a low-mannose glycan bound in the
CAP257-RH1 paratope. Previously, the N276 glycan on mono-
meric gp120 was characterized as being mostly complex in com-
position (51–53), but a more recent analysis of native prefusion
trimers suggests that this glycan is mostly oligomannose in com-
position and varies from MAN5 to MAN8 (54). Additional man-
nose residues could be modeled at the termini of each glycan arm
in the CAP257-RH1-bound structure, suggesting that this anti-
body’s binding was compatible with both NAG2MAN5 low-man-
TABLE 1 X-ray crystallographic data and refinement statistics
(molecular replacement) for the antigen binding fragment of CAP257-
RH1 in complex with the HIV-1 RHPA gp120 core
Parameter
Value for CAP257-RH1 bound




a, b, c (Å) 68.18, 71.14, 190.60
	, 
,  (°) 90, 90, 90
Resolution (Å) 50–3.21 (3.36–3.27, 3.27–3.21)
No. of unique reflections 13,003
Rmerge 0.102 (0.366, 0.381)
Rpim
c 0.059 (0.238, 0.271)
I/I 10.7 (2.3, 2.1)
Completeness (%) 82.0 (54.4, 33.1)
Redundancy 3.5 (2.7, 2.3)
Refinement statistics
Resolution (Å) 50–3.21
No. of reflections 12,967
Rwork/Rfree 0.23/0.27
No. of atoms (no H) 6,074
Protein 5,801
Glycan 273
B factors (no H) (Å2) 106
Protein 105
Glycan 140
Wilson B factor (Å2), all atoms 86
RMSa deviations
Bond lengths (Å) 0.002




Rotamer outliers (%) 0.5
MolProbity clash score 2.3
MolProbity overall score 1.5
C1 carbohydrate geometry (%) 100
a RMS, root mean square.
b Values in parentheses are for the highest-resolution shells.
c Precision-indicating merging R value.
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nose and NAG2MAN8/9 high-mannose glycans at position N276
(Fig. 4A). In both the CAP257-RH1- and 8ANC195-bound struc-
tures, the N276 glycan adopts a similar orientation that differs
substantially from the reoriented glycan conformation bound by
VRC01-like antibodies (Fig. 4B). Similarly, the CAP257-RH1-
bound orientation of the N276 glycan (Fig. 4C, left) was compat-
ible with HJ16-bound gp120 (by superimposing the gp120 mole-
cules from both structures) and packed closely against the HJ16
light chain in the model (Fig. 4C, right), which is indicative of a
common N276 glycan conformation bound by these neutralizing
antibodies. Thus, this structure of the N276 glycan may represent
a commonly occupied orientation of the N276 glycan bound by
bNAbs.
The CAP257-RH1 paratope is centered on its 11-amino-acid-
long CDR-H3, which accounts for 53% of the heavy chain in-
terface (Fig. 3D). The remaining heavy chain CDR loops were
positioned to interact with the conserved CD4bs, while the light
chain CDRs were more distal, in close proximity to V5. In concor-
FIG 3 Crystal structure of CAP257-RH1 bound to the N276 glycan in RHPA gp120. (A) Overview of the CAP257-RH1 Fab and RHPA core gp120 cocrystal
structure shown in a cartoon view. The truncated N/C termini as well as the V3 loop stem are labeled. Glycans are shown in stick view with green semitransparent
surfaces. The N276 glycan is indicated by its lighter shade. (B) Surface view of the HIV-1 Env trimer (PDB accession no. 4TVP) with monoclonal antibody
CAP257-RH1 docked into its epitope (by superimposition). The location of the viral membrane is indicated. (C) Surface view of RHPA gp120. Loop D and V5
are indicated, and the N276 glycan (shown in stick-and-surface view) is outlined. (D) Surface view of RHPA gp120 with the CD4 binding footprint. Loop D, V5,
and the N276 glycan are indicated as described above for panel C. The CAP257-RH1 CDRs are shown as thick blue cartoon loops. For clarity, the protein chain
is indicated in subscript (heavy chain, light chain, or gp120).
Wibmer et al.
10226 jvi.asm.org November 2016 Volume 90 Number 22Journal of Virology
 on A







dance with data from plasma mapping, CAP257-RH1 does not
interact productively with D368gp120 despite having a CDR-H2
that extended toward the CD4 binding loop (similarly to VRC01),
where H56HC forms a hydrogen bond with the S365gp120 backbone
carbonyl oxygen (Fig. 5A, left). The CDR-H1 and CDR-H3 loops
are both in close proximity to gp120 loop D, where E31HC and
D100aHC make hydrogen bonds with N279gp120 and N280gp120,
respectively (Fig. 5A, middle). The interaction between E31HC and
N279gp120 explains the antibody’s preference for an N279gp120 im-
munotype, as a negatively charged aspartic acid immunotype at
position 279gp120 would clash electrostatically with the glutamic
acid in CDR-H1. CDR-H3 also makes contact with the peptide
backbone of loop D and V5 through K99HC and with the D2 arm
of the N276 glycan through D101HC, while K32HC in CDR-H1 is
positioned to make weak contact with the first NAG moiety.
CAP257-RH1 also contacts the D1 arm of the N276 glycan via its
heavy chain N-terminal residue (Fig. 5A, right). In addition to these
heavy chain interactions, CDR-L2 of the light chain also contributes
to N276 glycan interactions by inserting F55LC between the second
NAG moiety and the D2 arm of the glycan as well as a hydrogen bond
with the backbone carbonyl of S56LC (Fig. 5A, right).
To evaluate the relative contributions of each of the contacts
identified above, alanine scanning mutants of the CAP257-RH1
paratope were made in the heavy chain (Fig. 5B) or light chain
(Fig. 5C) and assessed for their ability to neutralize RHPA. Heavy
chain mutations at K32HC in CDR-H1 and at H56HC in CDR-H2
marginally affected CAP257-RH1 neutralization, while the
E31AHC mutation had a much more substantial effect (Fig. 5B).
The reduction in the potency of the E31AHC mutant against RHPA
was equivalent to that of the wild-type antibody against the
N279Dgp120 mutant virus, consistent with the observed interac-
tion between these two residues (compare Fig. 2D and 5B). In
contrast to the CDR-H1/H2 contributions, all of the CDR-H3
mutants failed to neutralize RHPA, highlighting the important
role of this region in mediating neutralization. These data support
the classification of CAP257-RH1 as having a CDR-H3-domi-
nated paratope despite having a CDR-H3 loop length that is much
shorter than those of other HIV-1 CD4bs antibodies of this class.
FIG 4 Analysis of the N276 glycan bound by neutralizing antibodies. (A) CAP257-RH1 shown in cartoon view, as described in the legend of Fig. 3, interacting
with the N276 glycan (green sticks). The 2Fo  Fc electron density map (contoured at 1 ) of the N276 glycan is shown with black mesh. Additional mannose
moieties added to the glycan termini are shown in lime green, and the glycan arms are labeled. A schematic of the glycan is also shown at the bottom, and sugars
with visible density or those modeled onto the structure are labeled. (B) Comparison of the orientations of the N276 glycan bound by 8ANC195 (with Fab heavy
and light chains in peach and red, respectively), CAP257-RH1 (with Fab heavy and light chains in blue and cyan, respectively), or VRC01-like antibodies (with
Fab heavy and light chains in purple and pink, respectively). The Fab-bound glycan complexes (PDB accession no. 4P9H and 4JKP) were superimposed onto the
HIV-1 Env trimer structure reported under PDB accession no. 4TVP and are shown in light gray (gp120) and dark gray (gp41) surface views. (C, left) Surface view
of the N276 glycan bound by CAP257-RH1 (colored as for panel A). (Right) HJ16 cocrystal structure (PDB accession no. 4YE4) superimposed onto CAP257-
RH1-bound gp120 showing compatibility with this N276 glycan orientation.
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The CDR-L2 F55ALC mutant, which disrupts interactions with
the N276 glycan, was also unable to neutralize RHPA (Fig. 5C).
Two additional light chain contacts in CDR-L1 at positions K31LC
and W32LC also had a substantial contribution to CAP257-RH1
neutralization, but alanine mutations at these sites did not com-
pletely abrogate the antibody’s activity (Fig. 5C). While interac-
tions with the conserved CD4bs (loop D and the CD4 binding
loop) are mediated exclusively by the CAP257-RH1 heavy chain,
the light chain is positioned close to V5, with its CDR-L1 binding
perpendicularly over the V5 loop apex (Fig. 5D). Light chain in-
teractions with V5 account for 259 Å2 of buried surface area and
include extensive hydrogen bonding with the V5 peptide back-
bone and notable van der Waals contributions by the W32LC side
chain, which inserts behind V5 to contact the backbone carbonyl
of D461gp120. This displaces the D461gp120 side chain into the
CAP257-RH1 paratope, where it interacts with K31LC (Fig. 5D).
However, mutation of D461gp120 to alanine in the RHPA V5 loop
affected the IC50 but was not critical for neutralization, while mu-
tation of V460gp120 actually enhanced CAP257-RH1 neutraliza-
tion (Fig. 5E). Taken together, both heavy and light chain interac-
tions with the N276 glycan (D101HC and F55LC but not K32HC),
loop D (E31HC and D100aHC), or the base of V5 (K99HC) were
critical for CAP257-RH1 neutralization, while specific contacts
with the hypervariable V5 loop apex (K31LC and W32LC) were not
essential for neutralization and thus not the primary determinant
of CAP257-RH1 strain specificity.
CAP257-RH1 neutralization is incompatible with glycosy-
lated V5 loops. To better understand the strain specificity of
CAP257-RH1, the cocrystal structures of other CD4bs antibodies
were superimposed onto the cocrystal structure of CAP257-RH1
bound to RHPA gp120 (Fig. 6). Both N276 glycan-dependent an-
tibodies CAP257-RH1 and HJ16 infiltrated less substantially into
the CD4bs than the other CD4bs neutralizing antibodies (Fig. 6A).
The VH gene-restricted bNAbs VRC01 and CH235.12 were pre-
dicted to clash significantly with the CAP257-RH1-bound orien-
tation of the glycan at position N276, but the placement of this
glycan was compatible with all of the antibodies of the CDR-H3-
dominated class. These data are consistent with previously re-
ported observations that VH gene-restricted bNAbs bind better to
N276 glycan-deficient Env (31, 32, 55). Another striking differ-
ence between the CD4bs antibodies was their binding orientations
relative to V5. While VH gene-restricted CD4bs antibodies com-
FIG 5 Atomic details of the CAP257-RH1 interaction with RHPA core gp120. (A) Polar contacts between CAP257-RH1 and the CD4bs/N276 glycan. The
CAP257-RH1 CDRs are shown in various shades of blue, while the CD4b binding loop, loop D, and the N276 glycan are shown in gray, purple, and green,
respectively. Potential hydrogen bonds are shown as black dotted lines. (B) Paratope mapping of the CAP257-RH1 heavy chain by alanine scanning mutagenesis.
Mutations are grouped by CDR loop using different shades of blue. Percent inhibition is plotted on the y axis, and the antibody concentration is plotted on the
x axis. (C) Paratope mapping of the CAP257-RH1 light chain, as described above for panel B. (D) Atomic details of the interaction between CAP257-RH1
CDR-L1 (cyan) and the V5 loop of RHPA (red). Polar interactions are indicated as described above for panel A. (E) Neutralization of various RHPA alanine
mutants, plotted as described above for panel B.
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pletely avoided the V5 loop apex, the binding of CDR-H3-domi-
nated antibodies often placed their light chains in close proximity
to V5 (Fig. 6B). Overall, less penetration into the recessed CD4bs
and greater overlap of the V5 loop apex correlated with reduced
neutralization breadth. This was particularly prominent for N276
glycan-dependent CD4bs antibodies HJ16 and CAP257-RH1,
both of which increased their interacting surfaces with V5 through
a bulky tryptophan residue from the CDR-L3 or CDR-L1 loop,
respectively (shown in Fig. 6B). The extent of this overlap sug-
gested that the binding angles for these two antibodies were less
tolerant of longer or more glycosylated V5 loops than other
CD4bs antibodies such as VRC01.
The RHPA V5 loop is relatively short (5 amino acids between
positions 460 and 464) and unusually glycan-free (Fig. 6C). In-
deed, glycan-free V5 loops make up only 6% of the 5,000 HIV-1
group M Env sequences in the LANL database. To test whether
this lack of glycan contributed to CAP257-RH1 strain specificity,
V5-glycosylated sequence variants of RHPA were made and tested
for their sensitivity to CAP257-RH1, HJ16, and VRC01 (Fig. 6D).
All these V5 mutants were more resistant to the three CD4bs an-
tibodies tested, although the effect varied depending on the loca-
tion of the introduced glycosylation sequon. All the mutants were
marginally less sensitive to neutralization by VRC01, and this ef-
fect was more pronounced for V5 N-terminal glycan substitu-
tions. In contrast, HJ16 neutralization was knocked out by a gly-
can at position 460gp120 and substantially affected by a glycan site
at position 462gp120, while CAP257-RH1 neutralization was com-
pletely abrogated by the introduction of glycosylation sequons at
positions 460gp120, 461gp120, and 462gp120 and significantly affected
by a glycan at position 464gp120. A glycosylation sequon at position
463gp120 could not be tested because mutation of E465gp120 re-
sulted in nonfunctional virions. These data are consistent with the
level of V5 overlap displayed by each of these antibodies and sup-
port the hypothesis that CAP257-RH1 neutralization breadth is
substantially limited by V5 glycosylation.
A minority population of CAP257 autologous viruses lacks
glycans in V5. Donor CAP257 was infected with a clade C tier 2
virus, which, from the earliest autologous V5 loop consensus (7
FIG 6 CAP257-RH1 neutralization is constrained by V5 glycosylation. (A) Comparison of the relative levels of penetration into the recessed CD4bs for various
CD4bs neutralizing antibodies (crystal structures determined previously) superimposed onto the RHPA crystal structure, shown in surface view. The antibodies
are grouped as CDR-H3 dominated or VH gene restricted and ordered according to increasing neutralization breadth. N276 glycan-dependent antibodies are
indicated. For all antibodies, the light chains are shown in black, while the heavy chains are shown in various colors. (B) Comparison of the binding angles for the
CD4bs antibodies shown in panel A relative to RHPA V5, with the CAP257-RH1-bound N276 glycan shown as sticks with a semitransparent surface. All
antibodies are shown in cartoon view, with the heavy chains in white and the light chains colored according to neutralization breadth, as described above for panel
A. Previously reported neutralization breadth estimates are shown. (C) Zoomed view of the glycan-free RHPA V5 loop shown as sticks with a transparent surface,
with amino acids 460 to 464 being labeled. (D) Neutralization of RHPA and glycosylated V5 mutants by VRC01, HJ16, and CAP257-RH1. Percent inhibition is
plotted on the y axis, and the antibody concentration is plotted on the x axis.
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weeks postinfection), was glycosylated at position 461gp120 and
consequently resistant to CAP257-RH1 neutralization (see Tables
S1 and S5 in the supplemental material). To identify potential
autologous glycan-free V5 loops, a panel of 150 CAP257 Env
sequences isolated by single-genome amplification (SGA) at 16
time points throughout infection of donor CAP257 were exam-
ined, but all the sequences were glycosylated, making it unclear
which virus stimulated the CAP257-RH lineage (see Fig. S4 in
the supplemental material). The autologous CAP257 viral se-
quences were further probed by deep sequencing of the V3-to-V5
region of Env from 25 time points between 7 weeks (study enroll-
ment) and 202 weeks postinfection, resulting in 19,761 consensus
V5 sequences (Fig. 7A). The CAP257-RH lineage was isolated at
107 weeks postinfection, where the major viral population had
two glycans per V5 loop. However, at time points between 7 weeks
and 67 weeks postinfection, a minor population of CAP257 vi-
ruses was detected, with completely glycan-free V5 loops that were
dominated by a D461 immunotype (Fig. 7A, red spheres). These
sequences peaked in frequency (at 4.9% of total sequences) at 16
weeks postinfection (Fig. 7B), when the viral load was 32,000 cop-
ies/ml (equating to 1,568 RNA copies encoding glycan-free V5
Env sequences per ml of blood), but occurred less frequently after
the detection of CAP257 CD4bs neutralizing plasma antibodies at
54 weeks postinfection (Fig. 7C). A population of glycan-free V5
loops was consistently detectable at very low levels (1% of total
sequences) thereafter, alongside the evolving CAP257 CD4bs neu-
tralizing antibody response, but appeared to be spontaneously
generated and was unrelated to the initial glycan-free V5 loops
detected prior to the development of CD4bs antibodies.
To evaluate the potential effect of these glycan-free V5 loops on
the Env glycan shield, we modeled the surface coverage of
NAG2MAN9 glycans on the Env trimer. Accessibility to the under-
lying protein surface was evaluated by using probe radii of either
1.4 Å (the radius of a water molecule) or 10 Å (the approximate
radius of a single Fab domain) (Fig. 7D). This analysis revealed an
unprotected region of the Env protein surface, showing how a
glycan hole in V5 exposes epitopes for the induction of autologous
neutralizing antibodies such as CAP257-RH1.
DISCUSSION
The CD4bs on the HIV-1 envelope is the most extensively studied
site of vulnerability to antibody neutralization, but less is known
about how these antibodies arise in infection or how they might be
induced by vaccination. Here, we isolated and characterized a
CD4bs antibody called CAP257-RH1, which recognizes an N276
glycan-dependent epitope targeted by early members of the
CD4bs plasma bNAb response that developed in donor CAP257.
A cocrystal structure that included the N276 glycan revealed ex-
tensive contacts between the CAP257-RH1 heavy chain and con-
served elements of the CD4bs. Narrow neutralization breadth was
attributed to a light chain binding angle that was incompatible
with glycosylated V5 loops present in almost all HIV-1 strains.
Rare autologous sequences from donor CAP257 early in infection
were found to have glycan-free V5 loops that may have been re-
sponsible for engaging the naive B cell that produced this CD4bs
antibody lineage. Thus, vaccine immunogens that lack glycans in
V5 may provide better exposure for the epitopes targeted by N276
glycan-dependent CD4bs antibodies.
Although the CAP257-RH1 monoclonal antibody is strain spe-
cific for the heterologous virus RHPA, it targets the same N276
glycan-dependent CD4bs epitope as CAP257 plasma bNAbs. In
addition, CAP257-RH1 was very sensitive to the N279D mutation
that in plasma affected only the earliest CAP257 CD4bs neutraliz-
ing antibodies and coincided with the emergence of the later
broadly neutralizing CD4bs response. Thus, CAP257-RH1 likely
represents an early member of the neutralizing response to the
CD4bs in this individual. Three studies detailing the ontogeny of
bNAbs showed that they arose from strain-specific precursors (17,
18, 20). While strain-specific neutralizing antibodies have long
been known to target the hypervariable regions of Env (2, 3, 5–8),
it has become apparent that the epitopes for strain-specific anti-
bodies may also substantially overlap the epitopes for bNAbs (56,
57). For instance, 2909 is strain specific for the heterologous virus
SF162 and targets an epitope in V2 (58), but the isolation of PG9
and PG16 showed that this epitope was also vulnerable to bNAbs
(59). The limited neutralization breadth of 2909 could be ex-
plained by the requirement for a lysine at position 160 (normally
glycosylated) creating a hole in the Env glycan shield (57).
CAP257-RH1 specificity was similarly constrained by the require-
ment for a glycan-free V5 loop and a slight preference for the D461
immunotype. However, CAP257-RH1 still neutralized V5 alanine
mutants of RHPA and could conceivably mature to recognize
more diverse V5 loop sequences. Alternatively, these antibodies
may have helped drive viral diversity in the CD4bs, in turn pro-
moting the development of plasma neutralization breadth, similar
to the cooperative evolution of the CH103 and CH235 lineages in
donor CH505 (21). It is not known whether the CAP257-RH lin-
eage also went on to develop broadly neutralizing activity, and the
isolation of CD4bs bNAbs from donor CAP257 would help to
address this question.
CAP257-RH1 together with HJ16 and 179NC75 form a sub-
class of CDR-H3-dominated CD4bs antibodies (26, 28) that are
critically dependent on the N276 glycan but not D368 (28, 36, 60).
CAP257-RH1 binds the N276 glycan in a recess created by the
antibody heavy chain-light chain interface and recognizes the gly-
can with an orientation similar to that of bNAb 8ANC195 that
targets the gp120-gp41 interface (49, 61). This glycan orientation
could also be accommodated by glycan-dependent CD4bs anti-
body HJ16 in our modeling analysis but not by the VH gene-
restricted antibodies, which clash sterically with N276, consistent
with previously reported crystal structures showing the relocation
of this glycan by VRC01 and related antibodies (48, 50). The de-
gree of similarity in N276 glycan recognition is comparable to that
of the N332 glycan supersite, which is oriented in the same con-
formation by antibodies with very different epitopes and angles of
approach (62). Together with more recent insights into the struc-
ture of the glycan shield (50, 54), these data help to define the role
of N276 in bNAb development. HJ16 and other CDR-H3-domi-
nated class bNAbs increase interactions with the CD4 binding
pocket through long CDR-H3 loops. CAP257-RH1 binds to the
periphery of the CD4bs but does not extend deep into the confor-
mationally occluded CD4 binding pocket, and its deviation from
the previously described CD4bs of vulnerability results in a nar-
row neutralization breadth.
CAP257-RH1 was unable to neutralize viruses with glycosy-
lated V5 loops, including the CAP257 transmitted/founder virus.
We speculate that the CAP257-RH lineage was elicited by low-
frequency autologous variants that had glycan-free V5 loops.
These viruses never came to dominate the viral population, pos-
sibly due to selection pressures imposed by the CAP257-RH lin-
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FIG 7 Rare glycan-free V5 sequences from CAP257 reveal a hole in the glycan shield. (A) Deep sequencing of autologous V5 loop sequences in donor CAP257,
with the number of glycans on the y axis and weeks postinfection on the x axis. The relative frequencies of the number of glycans in V5 at a particular time point
are represented by the size of the spheres, where larger spheres indicate a greater relative number of sequences at that particular time point that have the indicated
number of glycosylation sequons in V5. The dotted vertical line indicates the time point at which CAP257-RH1 was isolated. (B) Relative number of glycan-free
autologous V5 loops plotted as a percentage of the total sequences (y axis) over time (x axis). (C) Neutralization titers (plotted on the y axis) of the second wave
of broadly neutralizing antibodies from donor CAP257 plasma (as described in reference 36), which target the CD4bs, over time (x axis). (D, left) The HIV-1 Env
trimer is shown in a solvent-accessible surface representation (gray). The approximate location of the viral membrane is indicated. (Right) The glycan shield is
modeled and displayed as the solvent-accessible surface of NAG2MAN9 glycan coverage based on two probe sizes of 1.4 Å (solvent radius) (top) and 10.0 Å (the
estimated steric footprint of an antibody-combining region) (bottom), using the structure reported under PDB accession no. 4TVP with an additional
glycosylation site modeled at residue 241. The solvent-accessible protein surface of V5 comprises a largely exposed region upon the deletion of the commonly
glycosylated site at residue 462 (right).
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eage. Alternatively, it is also possible that rare glycan-skipping
events in V5 (where glycosylation sequons are missed by oligosac-
charyltransferase in the Golgi apparatus) stimulated the lineage.
Interestingly, in another individual (donor CAP256) who devel-
oped broad and potent V2-reactive antibodies from a strain-spe-
cific precursor (17, 63), the bNAb-initiating Env was also found to
be relatively rare compared to the dominantly circulating viral
variant (64). Similarly to the CAP257-RH1 epitope, several other
studies have also identified strain-specific neutralizing antibody
targets created by unusual holes in the glycan shield (22, 58, 65,
66). These targets include vaccine-induced antibodies (67, 68),
such as the strain-specific macaque antibody DH427, which tar-
gets a large glycan hole in both V5 and loop E, allowing an angle of
approach that does not include the CD4bs, and therefore is un-
likely to mature toward neutralization breadth. In donor 45, from
which VRC01 was isolated, proviral sequences with a rare hole in
the glycan shield at position N276 were identified (69, 70), which
may represent rare bNAb-initiating Envs that set off the VRC01-
like lineages in this donor. Thus, glycan holes may elicit highly
strain-specific responses that are unable to further mature toward
neutralization breadth but may also represent key features of
HIV-1 immunogens that engage the appropriate precursors of
HIV-1 bNAbs. While these holes may recruit the appropriate na-
ive B cells, driving the process toward breadth will likely require
the addition of fully glycosylated native trimeric immunogens that
select for mutations that are able to accommodate the Env glycan
shield (34, 35).
Immunogens designed to activate VRC01 class VH gene-re-
stricted CD4bs bNAb precursors have so far shown promising
results in animal studies. These antigens not only lack the N276
glycan but also have been modified to bind with higher affinity to
the VH1-2 germ line gene (31, 32). Germ line gene knock-in mice
immunized with these constructs produced antibodies with neu-
tralization-compatible mouse light chains (34, 35), and germ line-
targeting antigens preferentially select for VH gene-restricted pre-
cursors in healthy individuals (71). In addition to N276 mutants,
Env immunogens that also lack glycans in V5 bind even better to
the VH gene-restricted CD4bs bNAb precursors (32). In this
study, we show that viruses lacking glycans in V5 are also consid-
erably better neutralized by N276 glycan-dependent antibodies.
This subclass of CD4bs antibodies would not be elicited by the
N276-deficient Env immunogens designed to elicit VH gene-re-
stricted antibodies. Based on the CAP257-RH1 cocrystal struc-
ture, glycan-free V5 may have been expressly required for activat-
ing the CAP257-RH lineage, and immunogens incorporating this
feature may also improve binding to the precursors of other N276
glycan-dependent antibodies.
Altogether, these data provide insights into the N276 glycan as
a target for HIV-1 neutralizing CD4bs antibodies and the types of
immunogens that might be required to activate their naive B-cell
precursors. Further isolation and characterization of N276 gly-
can-dependent bNAbs will be important for understanding how
CD4bs immunogens might better capture the entire repertoire of
bNAb precursors by immunization. Future studies will aim at
assessing the role of glycan holes in priming B-cell responses that
might mature to acquire broadly neutralizing activity.
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